Unaudited Financial Results for the quarter and nine months ended December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved unaudited financial results for Q3 FY26 and nine months ended December 31, 2025. Revenue from operations nearly doubled year-on-year to ₹2,164.41 lakhs in Q3 (vs ₹1,150.06 lakhs) and grew ~70% to ₹5,398.75 lakhs for nine months (vs ₹3,176.65 lakhs). The growth was driven mainly by the new Energy segment (₹703.18 lakhs in Q3 vs ₹250.00 lakhs) while Ayurveda grew modestly. Despite strong revenue, profit after tax fell to ₹82.38 lakhs in Q3 (vs ₹101.81 lakhs) and ₹215.47 lakhs for nine months (vs ₹227.74 lakhs), as expenses scaled up much faster than profits and EBITDA margins compressed sharply. The auditor issued a clean limited review report with no qualifications.
Strong top-line growth signals business expansion, but the sharp decline in profitability and EBITDA margin compression suggest rising input or scaling costs that may concern investors looking at earnings quality. The ₹10 crore loan and equity infusion into subsidiaries for green energy projects ties future returns to execution of new projects.